Systemic Treatments for the Management of Prurigo Nodularis
A dermatology expert provides comprehensive insights into prurigo nodularis, discussing its disproportionate impact on middle-aged adults and immunocompromised individuals, the evolution of treatment from traditional dermatologic therapies to FDA-approved biologics (dupilumab and nemolizumab), and the importance of addressing both the physical symptoms and psychological burden while considering patient-specific factors such as comorbidities in treatment selection.
